FR3041640B1 - NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT - Google Patents

NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT Download PDF

Info

Publication number
FR3041640B1
FR3041640B1 FR1559259A FR1559259A FR3041640B1 FR 3041640 B1 FR3041640 B1 FR 3041640B1 FR 1559259 A FR1559259 A FR 1559259A FR 1559259 A FR1559259 A FR 1559259A FR 3041640 B1 FR3041640 B1 FR 3041640B1
Authority
FR
France
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
pyrimidine derivatives
novel pyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1559259A
Other languages
English (en)
French (fr)
Other versions
FR3041640A1 (enExample
Inventor
Andrea Fiumana
Nicolas Foloppe
Stuart Ray
David WALMSLEY
Andras Kotschy
Frank Burbridge Michael
Francisco Humberto CRUZALEGUI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Vernalis R&D Ltd
Original Assignee
Laboratoires Servier SAS
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1559259A priority Critical patent/FR3041640B1/fr
Application filed by Laboratoires Servier SAS, Vernalis R&D Ltd filed Critical Laboratoires Servier SAS
Priority to US15/763,626 priority patent/US20180273538A1/en
Priority to MA043021A priority patent/MA43021A/fr
Priority to KR1020187012166A priority patent/KR20180054856A/ko
Priority to CA2999937A priority patent/CA2999937A1/en
Priority to MX2018003861A priority patent/MX2018003861A/es
Priority to CR20180176A priority patent/CR20180176A/es
Priority to BR112018005851A priority patent/BR112018005851A2/pt
Priority to AU2016333508A priority patent/AU2016333508A1/en
Priority to CN201680058179.3A priority patent/CN108137582A/zh
Priority to PCT/EP2016/073403 priority patent/WO2017055533A1/en
Priority to TNP/2018/000087A priority patent/TN2018000087A1/en
Priority to EP16774684.1A priority patent/EP3356364A1/en
Priority to HK18114640.5A priority patent/HK1255467A1/zh
Priority to PE2018000410A priority patent/PE20190337A1/es
Priority to JP2018516488A priority patent/JP2018533552A/ja
Priority to CUP2018000027A priority patent/CU20180027A7/xx
Priority to EA201890820A priority patent/EA201890820A1/ru
Publication of FR3041640A1 publication Critical patent/FR3041640A1/fr
Priority to IL258231A priority patent/IL258231A/en
Priority to PH12018500605A priority patent/PH12018500605A1/en
Priority to SV2018005656A priority patent/SV2018005656A/es
Priority to NI201800042A priority patent/NI201800042A/es
Priority to ECIEPI201823286A priority patent/ECSP18023286A/es
Priority to DO2018000082A priority patent/DOP2018000082A/es
Priority to CL2018000786A priority patent/CL2018000786A1/es
Priority to CONC2018/0003466A priority patent/CO2018003466A2/es
Application granted granted Critical
Publication of FR3041640B1 publication Critical patent/FR3041640B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR1559259A 2015-09-30 2015-09-30 NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT Expired - Fee Related FR3041640B1 (fr)

Priority Applications (26)

Application Number Priority Date Filing Date Title
FR1559259A FR3041640B1 (fr) 2015-09-30 2015-09-30 NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
JP2018516488A JP2018533552A (ja) 2015-09-30 2016-09-30 二重ｄｙｒｋ１／ｃｌｋ１阻害剤としての新規なピロロ［２，３−ｄ］ピリミジン誘導体
KR1020187012166A KR20180054856A (ko) 2015-09-30 2016-09-30 이중 dyrk1/clk1 억제제로서의 신규한 피롤로[2,3-d]피리미딘 유도체
CA2999937A CA2999937A1 (en) 2015-09-30 2016-09-30 New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors
MX2018003861A MX2018003861A (es) 2015-09-30 2016-09-30 Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparacion y composiciones farmaceuticas que los contienen.
CR20180176A CR20180176A (es) 2015-09-30 2016-09-30 NUEVOS DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
BR112018005851A BR112018005851A2 (pt) 2015-09-30 2016-09-30 derivados de pirrolo[2,3-d]pirimidina como inibidores de dyrk1 / clk1 duais
AU2016333508A AU2016333508A1 (en) 2015-09-30 2016-09-30 New pyrrolo[2,3-d]pyrimidine derivatives as dual DYRK1/CLK1 inhibitors
CN201680058179.3A CN108137582A (zh) 2015-09-30 2016-09-30 作为双重DYRK1/CLK1抑制剂的新的吡咯并[2,3-d]嘧啶衍生物
PCT/EP2016/073403 WO2017055533A1 (en) 2015-09-30 2016-09-30 New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors
TNP/2018/000087A TN2018000087A1 (en) 2015-09-30 2016-09-30 New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors
EP16774684.1A EP3356364A1 (en) 2015-09-30 2016-09-30 New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors
HK18114640.5A HK1255467A1 (zh) 2015-09-30 2016-09-30 作为双重dyrk1/clk1抑制剂的新的吡咯并[2，3-d]嘧啶衍生物
PE2018000410A PE20190337A1 (es) 2015-09-30 2016-09-30 NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
US15/763,626 US20180273538A1 (en) 2015-09-30 2016-09-30 PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CUP2018000027A CU20180027A7 (es) 2015-09-30 2016-09-30 DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, ÚTILES COMO INHIBIDORES DOBLES DE DYRK 11CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
MA043021A MA43021A (fr) 2015-09-30 2016-09-30 Nouveaux dérivés pyrrolo [2,3-d]pyrimidine utilisés en tant qu'inhibiteurs doubles de dyrk1/clk1
EA201890820A EA201890820A1 (ru) 2015-09-30 2016-09-30 НОВЫЕ ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1
IL258231A IL258231A (en) 2015-09-30 2018-03-19 New pyrrolo[2,3-d]pyrimidine derivatives as dual dyrk1/clk1 inhibitors
PH12018500605A PH12018500605A1 (en) 2015-09-30 2018-03-20 New pyrrolo[2,3-d]pyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
SV2018005656A SV2018005656A (es) 2015-09-30 2018-03-22 Nuevos derivados de pirrolo[2,3-d]pirimidina,un proceso para su preparacion y composiciones farmaceuticas que los contiene
NI201800042A NI201800042A (es) 2015-09-30 2018-03-23 Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1
DO2018000082A DOP2018000082A (es) 2015-09-30 2018-03-26 NUEVOS DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CL2018000786A CL2018000786A1 (es) 2015-09-30 2018-03-26 Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen.
ECIEPI201823286A ECSP18023286A (es) 2015-09-30 2018-03-26 NUEVOS DERIVADOS DE PIRROLO[2,3-d]PIRIMIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CONC2018/0003466A CO2018003466A2 (es) 2015-09-30 2018-03-28 Nuevos derivados de pirrolo[2,3-d]pirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1559259A FR3041640B1 (fr) 2015-09-30 2015-09-30 NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
FR1559259 2015-09-30

Publications (2)

Publication Number Publication Date
FR3041640A1 FR3041640A1 (enExample) 2017-03-31
FR3041640B1 true FR3041640B1 (fr) 2019-05-17

Family

ID=54979756

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1559259A Expired - Fee Related FR3041640B1 (fr) 2015-09-30 2015-09-30 NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT

Country Status (26)

Country Link
US (1) US20180273538A1 (enExample)
EP (1) EP3356364A1 (enExample)
JP (1) JP2018533552A (enExample)
KR (1) KR20180054856A (enExample)
CN (1) CN108137582A (enExample)
AU (1) AU2016333508A1 (enExample)
BR (1) BR112018005851A2 (enExample)
CA (1) CA2999937A1 (enExample)
CL (1) CL2018000786A1 (enExample)
CO (1) CO2018003466A2 (enExample)
CR (1) CR20180176A (enExample)
CU (1) CU20180027A7 (enExample)
DO (1) DOP2018000082A (enExample)
EA (1) EA201890820A1 (enExample)
EC (1) ECSP18023286A (enExample)
FR (1) FR3041640B1 (enExample)
HK (1) HK1255467A1 (enExample)
IL (1) IL258231A (enExample)
MA (1) MA43021A (enExample)
MX (1) MX2018003861A (enExample)
NI (1) NI201800042A (enExample)
PE (1) PE20190337A1 (enExample)
PH (1) PH12018500605A1 (enExample)
SV (1) SV2018005656A (enExample)
TN (1) TN2018000087A1 (enExample)
WO (1) WO2017055533A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20180094A1 (ar) 2017-10-18 2019-04-18 Hk Inno N Corp مركب حلقي غير متجانس كمثبط بروتين كيناز
KR102054910B1 (ko) * 2017-12-19 2019-12-12 한림제약(주) 피롤로[2,3-d]피리미딘 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CA3118093A1 (en) 2018-09-28 2020-04-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk1/clk and uses thereof
CN113227089B (zh) 2018-10-31 2024-07-05 吉利德科学公司 作为hpk1抑制剂的取代的6-氮杂苯并咪唑化合物
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CN110407744A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种1-(4-氨基吡啶-2-基)乙酮的合成方法
AR120799A1 (es) * 2019-12-20 2022-03-16 Hoffmann La Roche 2-[4-cloro-6-[2-[4-[[4-(hidroximetil)-1-piperidil]metil]fenil]etinil]-1-oxoisoindolin-2-il]-2-(6,7-dihidro-5h-pirrolo[1,2-c]imidazol-1-il)-n-tiazol-2-il-acetamida como inhibidor de egfr
CN116783198B (zh) * 2020-12-02 2025-10-21 广东弘烨医药科技有限公司 螺环jak抑制剂、含其的药物组合物及其应用
US20240261297A1 (en) * 2021-05-20 2024-08-08 St. John's Cancer Institute Anti-cdk inhibitors for cancer treatment
TW202330533A (zh) * 2021-10-12 2023-08-01 美商生物銜接醫療公司 7h-吡咯并[2,3-d]嘧啶及其製備及用途
US12134625B2 (en) 2021-10-12 2024-11-05 Biosplice Therapeutics, Inc. Pyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof
US20230192686A1 (en) * 2021-10-12 2023-06-22 Biosplice Therapeutics, Inc. 1h-pyrrolo[2,3-b]pyridines and preparation and uses thereof
WO2023110843A1 (en) * 2021-12-15 2023-06-22 Almirall, S.A. Heterobicyclic derivatives as itk inhibitors
CN116621843B (zh) * 2022-06-13 2024-05-24 四川大学华西医院 一种dna甲基转移酶1抑制剂及其制备方法和用途
CN115785134B (zh) * 2022-10-28 2023-08-29 浙大城市学院 一种含氮杂环的硼酸化合物及制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006343808B2 (en) 2005-05-20 2012-03-29 Mirati Therapeutics, Inc. Inhibitors of VEGF receptor and HGF receptor signaling
EP1948659A1 (en) 2005-10-13 2008-07-30 Glaxo Group Limited Pyrrolopyrimidine derivatives as syk inhibitors
EP2007767B1 (en) 2006-03-11 2011-11-02 Vernalis (R&D) Ltd Pyrrolopyrimidine derivatives used as hsp90 inhibitors
FR2912744B1 (fr) * 2007-02-16 2012-09-07 Centre Nat Rech Scient Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations.
AR070127A1 (es) 2008-01-11 2010-03-17 Novartis Ag Pirrolo - pirimidinas y pirrolo -piridinas
KR20150027267A (ko) * 2012-06-29 2015-03-11 화이자 인코포레이티드 LRRK2 억제제로서의 4-(치환된-아미노)-7H-피롤로[2,3-d]피리미딘
US9695171B2 (en) * 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors

Also Published As

Publication number Publication date
CR20180176A (es) 2018-05-31
MA43021A (fr) 2018-08-08
BR112018005851A2 (pt) 2018-10-09
CA2999937A1 (en) 2017-04-06
SV2018005656A (es) 2018-08-10
CO2018003466A2 (es) 2018-07-10
KR20180054856A (ko) 2018-05-24
NI201800042A (es) 2018-06-21
WO2017055533A1 (en) 2017-04-06
ECSP18023286A (es) 2018-04-30
DOP2018000082A (es) 2018-10-15
PE20190337A1 (es) 2019-03-07
CN108137582A (zh) 2018-06-08
PH12018500605A1 (en) 2018-09-24
TN2018000087A1 (en) 2019-07-08
FR3041640A1 (enExample) 2017-03-31
MX2018003861A (es) 2018-08-16
EA201890820A1 (ru) 2018-10-31
AU2016333508A1 (en) 2018-04-12
CL2018000786A1 (es) 2018-09-28
JP2018533552A (ja) 2018-11-15
US20180273538A1 (en) 2018-09-27
CU20180027A7 (es) 2018-07-05
HK1255467A1 (zh) 2019-08-16
EP3356364A1 (en) 2018-08-08
IL258231A (en) 2018-05-31

Similar Documents

Publication Publication Date Title
FR3041640B1 (fr) NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
FR2986002A1 (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA37206B1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MA37213B1 (fr) Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CL2020002922A1 (es) Derivados de tetrahidro-imidazo[4,5-c]piridina como inmunomoduladores de pd-l1.
FR3037958B1 (fr) Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EA201791692A1 (ru) 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
EP3481831A4 (en) INNOVATIVE 4-AMINOPYRAZOLO [3,4-D] PYRIMIDINYLAZABICYCLO DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREFOR
MX383856B (es) Compuestos y composiciones para inhibir la actividad de shp2.
MX2015009602A (es) Piridona amidas como moduladores de canales de sodio.
MX380122B (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
TN2016000014A1 (fr) Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
CL2015002303A1 (es) Derivados de pirrolo[2,3-d]pirimidina
MX374191B (es) Derivados de nucleósido sustituidos con 4´ -difluorometilo como inhibidores de la replicación de arn de la influenza.
UY36265A (es) “derivados de pirrolo[2,3-d]pirimidina”.
MX2015009591A (es) Amidas como moduladores de canales de sodio.
MA40236A (fr) Formes cristallines de (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-méthanpyrido[1',2':4,5]pyrazino 2,1-b][1,3]oxazépine-10-carboxamide
CL2020001073A1 (es) Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
CY1123880T1 (el) Καινοτομοι 5-ητ2 ανταγωνιστες
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
DOP2018000083A (es) NUEVOS DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CL2018003610A1 (es) Nuevos derivados de [1,2,3]triazolo[4,5-d]pirimidina.
CU20130124A7 (es) Derivados de tieno [2,3-d] pirimidina y su uso para el tratamiento de la arritmia

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20170331

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

ST Notification of lapse

Effective date: 20200906